When should clinicians order genetic testing for Dravet syndrome?

Area of Science:

• Genetics
• Neurology
• Pediatrics

Background:

• Dravet syndrome is strongly linked to mutations in the SCN1A gene.
• Phenotypic variability means some patients may not meet all International League Against Epilepsy (ILAE) criteria for Dravet syndrome.
• Accurate genetic diagnosis is essential for appropriate patient management.

Purpose of the Study:

• To evaluate the predictive value of ILAE criteria for SCN1A mutations in children with suspected Dravet syndrome.
• To identify key clinical features that best predict SCN1A mutations.
• To develop a high-sensitivity strategy for SCN1A mutation detection.

Main Methods:

• Retrospective analysis of a consecutive cohort of children undergoing genetic testing.
• Evaluation of International League Against Epilepsy (ILAE) criteria in relation to SCN1A mutation status.
• Statistical analysis to determine the sensitivity and predictive value of specific criteria.

Main Results:

• SCN1A mutations were identified in 16 out of 69 children.
• Meeting four or more ILAE criteria demonstrated 100% sensitivity for detecting SCN1A mutations.
• Key predictors included hyperthermia exacerbation, normal development before seizure onset, and specific neurological signs (ataxia, pyramidal signs, myoclonus).

Conclusions:

• The International League Against Epilepsy criteria, when applied comprehensively, offer a sensitive approach to identifying children with SCN1A mutations.
• Specific clinical features significantly enhance the prediction of SCN1A mutations in Dravet syndrome.
• This strategy aids in timely diagnosis and management of SCN1A-related epilepsies.